Appareil pulmonaire NIVOTHYM (EORTC-1525) Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Paris NICOLAS GIRARD
Recherches "plusieurs pathologies" RAGNAR (42756493CAN2002) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene;Alterations Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire SAVANNAH (D5084C00007) Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in;Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally;Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed;Following Treatment with Osimertinib (The SAVANNAH Study) Paris NICOLAS GIRARD
Appareil pulmonaire SKYSCRAPER-06 (BO42592) A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer. Paris
VADS SKYSCRAPER-09 (BO42533) A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck. Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire HERTHENA-Lung01 U31402-A-U201 HERTHENA-Lung01: A Phase 2 Randomized Open-Label;Study of Patritumab Deruxtecan (U3-1402) in Subjects with;Previously Treated Metastatic or Locally Advanced EGFRmutated;Non-Small Cell Lung Cancer (NSCLC) Paris NICOLAS GIRARD
Appareil pulmonaire TROPION-Lung05 (DS1062-A-U202) Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed on or After Kinase Inhibitor Therapy and Platinum Based Chemotherapy (TROPION-Lung05) Paris NICOLAS GIRARD
VADS BGB-HNSCC-201 A Randomized, Phase 2, Open-Label, Multi-Arm;Study of Tislelizumab in Combination With;Investigational Agents as First-Line Treatment in;Patients With Recurrent or Metastatic Head and Neck;Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire DS 73001-003 A PHASE 2, MULTICENTER, RANDOMIZED, OPENLABEL;STUDY OF DS-7300A, A B7-H3 ANTIBODY;DRUG CONJUGATE (ADC), IN SUBJECTS WITH;PRETREATED EXTENSIVE-STAGE SMALL CELL;LUNG CANCER (ES-SCLC). Paris PAULINE DU RUSQUEC
VADS 219885 219885 GALAXIES H&N-202 A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck Paris CHRISTOPHE LE TOURNEAU